NAD+ 1G & RETATRUTIDE : A UK REPORT

The recent interest in NAD+ supplementation, particularly at a high dosage of 1g , continues to gain momentum within the UK healthcare community. Simultaneously , attention is focused on Retatrutide, a groundbreaking GLP-1 analogue being viewed by many as a potential advancement to Tirzepatide. R